Iwicki Mark T. - 21 Feb 2025 Form 4/A - Amendment Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role: Chief Executive Officer, Director
Signature: /s/ Mark Iwicki
Issuer symbol: IKT
Transactions as of: 21 Feb 2025
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 02 Jul 2025, 19:56:12 UTC
Date Of Original Report: 25 Feb 2025
Previous filing: 19 Feb 2025
Next filing: 26 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Iwicki Mark T	Chief Executive Officer, Director	1000 N. WEST STREET, SUITE 1200, WILMINGTON	/s/ Mark Iwicki	02 Jul 2025	0001415537

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKT	Stock Option (Right to Buy)	Award	$0	+602,346		$0.000000	602,346	21 Feb 2025	Common Stock	602,346	$2.97	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the "Option Award"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award.
F2	The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date.